Suzhou Ribo Life Science Co. Ltd. Adopts ArisGlobal’s LifeSphere® MultiVigilance to Advance Data Management from Clinical Trials
Innovative R&D company selects LifeSphere by ArisGlobal to further develop its safety capabilities MIAMI, Nov. 1, 2021 /PRNewswire/ -- ArisGlobal, the leading provider of life sciences software that automates core drug development with its end-to-end drug development technology platform LifeSphere® today announced its partnership with Suzhou Ribo Life Science Co., Ltd., an innovative...
Antengene Receives FDA Approval of IND for Phase 1 Trial of ATG-101 (PD-L1/4-1BB bispecific antibody) in Solid Tumors and Non-Hodgkin Lymphoma
SHANGHAI and HONG KONG, Nov. 1, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application...
Gannex Announces U.S. IND Approval of ASC43F, a First-in-Class Dual-Target Fixed-Dose Combination for NASH
SHANGHAI, Nov. 1, 2021 /PRNewswire/ -- Gannex Pharma Co., Ltd., a wholly owned company of Ascletis Pharma Inc. (HKEX: 1672), today announces the Investigational New Drug (IND) application approval by U.S. Food and Drug Administration (FDA) and initiation of global development of ASC43F, a first-in-class, fixed-dose combination (FDC) with dual targets of thyroid hormone receptor beta (THRβ) and farnesoid X receptor...
Farrer Park Hospital Introduced Actinium-225 PSMA Nuclear Therapy for Advanced Prostate Cancer
Earlier trials using Actinium-225 PSMA showed an improved biochemical response and better cancer-killing effects as Actinium-225 PSMA uses a much more potent radioactive ligand. SINGAPORE, Nov. 1, 2021 /PRNewswire/ -- Prostate cancer is the 3rd most common cancer among Singaporean men. Every day for years 2014-2018, 15% of new cancer cases for men were prostate cancer cases; more than 50% occurred...
HOPSTEM completed 40 million USD series B financing, to develop safe, effective and affordable iPSC cell therapies for global patients
CAYMAN ISLANDS, British Overseas Territory, Oct. 31, 2021 /PRNewswire/ -- After A++ financing in May this year, HOPSTEM announced that the company has completed a round of near 40 million USD Series B financing, led by a top VC/PE in biomedical field, followed by Lilly Asia Ventures and current shareholder YuanBio Venture Capital. According to the company, this round...
Everest Medicines Announces Share Repurchase Transaction Details
SHANGHAI, Nov. 1, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest" or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Asia, today announced that it has repurchased 1,095,000 ordinary shares equivalent to approximately HK$50 million in the open market in the period from October 4, 2021...
Invetech Named Victorian Top Exporter of the Year
MELBOURNE, Australia, Oct. 30, 2021 /PRNewswire/ -- Invetech, an end-to-end commercialisation partner to world's foremost therapeutic and diagnostic companies, has been named the Victorian Exporter of the Year at the 2021 Governor of Victoria Export Awards (GOVEA). Invetech also won the International Health category award. Invetech has been named the Victorian...
In response to WHO’s call, yoboo supports breastfeeding
MANILA, Philippines, Oct. 29, 2021 /PRNewswire/ -- In recent years, as the WHO's advocacy for breastfeeding has continued to deepen, the Philippines has organized several collective breastfeeding activities. As a professional medical mother and baby brand, yoboo is a loyal supporter of breast-feeding. yoboo actively participate in local offline publicity activities in the Philippines, and bring advanced medical parenting...
Award-winning abstracts confirm benefits of Elekta Unity in precision radiation therapy
CHICAGO, Oct. 29, 2021 /PRNewswire/ -- Elekta (EKTA-B.ST) today announced the presentation of new award-winning abstracts supporting the many benefits of Elekta Unity in treating cancer patients using precision radiation therapy. The abstracts add to the growing body of data manifesting Elekta Unity's unique capabilities, to the benefit of patients around the world. The system is highly appreciated by...
Novavax Files for Provisional Approval of its COVID-19 Vaccine in Australia
-- Application marks the first protein-based COVID-19 vaccine submitted to regulatory authorities for provisional approval in Australia -- In addition to today's submission to the Therapeutic Goods Administration, the company recently filed for authorization with MHRA, with additional filings in process -- All modules required for Australian regulatory evaluation, including Quality/...
